Tenwise

TenWise is a private, early-revenue service provider operating at the intersection of AI, bioinformatics, and life sciences. The company's primary asset is the KMAP platform, which aggregates and structures public biological knowledge to offer data interpretation, literature mining, and AI implementation consultancy services to pharmaceutical, biotech, and governmental clients. With a lean team led by industry veterans, TenWise focuses on delivering fast, client-owned insights to accelerate R&D decision-making in areas like microbiomics, transcriptomics, and alternative testing methods (3Rs/NAMs). The company operates as a B2B service provider rather than developing its own therapeutic pipeline.

KMAP platform: An integrated knowledge base combining data from numerous biological databases and scientific literature, enhanced with proprietary ontologies for entities like genes, microbes, metabolites, and diseases. It enables large-scale text mining and biological data interpretation.

TenWise competes with broad AI drug discovery platforms (e.g., BenevolentAI, Exscientia) and large commercial literature databases (e.g., Elsevier). Its differentiation lies in its niche focus on microbiomics and 3Rs, its custom-built ontologies within the KMAP platform, and a flexible service model that provides direct expert collaboration.